Walvax Biotechnology (300142) Stock Overview
Engages in the research and development, manufacture, and distribution of vaccines in China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
300142 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Walvax Biotechnology Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥13.26 |
| 52 Week High | CN¥16.23 |
| 52 Week Low | CN¥10.88 |
| Beta | 0.38 |
| 1 Month Change | 5.91% |
| 3 Month Change | 11.62% |
| 1 Year Change | -0.15% |
| 3 Year Change | -52.04% |
| 5 Year Change | -84.01% |
| Change since IPO | 18.71% |
Recent News & Updates
Recent updates
Shareholder Returns
| 300142 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | -5.2% | -4.2% | -4.7% |
| 1Y | -0.2% | -23.8% | 10.6% |
Return vs Industry: 300142 exceeded the CN Biotechs industry which returned -23.8% over the past year.
Return vs Market: 300142 underperformed the CN Market which returned 10.6% over the past year.
Price Volatility
| 300142 volatility | |
|---|---|
| 300142 Average Weekly Movement | 9.0% |
| Biotechs Industry Average Movement | 7.1% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in CN Market | 12.3% |
| 10% least volatile stocks in CN Market | 4.3% |
Stable Share Price: 300142 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 300142's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 1,981 | Wei Yao | www.walvax.com |
Walvax Biotechnology Co., Ltd., engages in the research and development, manufacture, and distribution of vaccines in China and internationally. Its vaccine portfolio includes recombinant human papillomavirus bivalent, 13-valent pneumococcal polysaccharide conjugate, 23-valent pneumococcal polysaccharide, group ACYW135 meningococcal polysaccharide, group A and C meningococcal polysaccharide, group A and group C meningococcal conjugate, and haemophilus influenzae type b conjugate vaccines, as well as diphtheria, tetanus and acellular pertussis combined vaccine. The company was founded in 2001 and is headquartered in Kunming, China.
Walvax Biotechnology Co., Ltd. Fundamentals Summary
| 300142 fundamental statistics | |
|---|---|
| Market cap | CN¥21.21b |
| Earnings (TTM) | CN¥285.77m |
| Revenue (TTM) | CN¥2.40b |
Is 300142 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300142 income statement (TTM) | |
|---|---|
| Revenue | CN¥2.40b |
| Cost of Revenue | CN¥639.95m |
| Gross Profit | CN¥1.76b |
| Other Expenses | CN¥1.47b |
| Earnings | CN¥285.77m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
Aug 29, 2026
| Earnings per share (EPS) | 0.18 |
| Gross Margin | 73.33% |
| Net Profit Margin | 11.91% |
| Debt/Equity Ratio | 17.3% |
How did 300142 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/23 01:52 |
| End of Day Share Price | 2026/07/23 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Walvax Biotechnology Co., Ltd. is covered by 7 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Xiao Wei Lin | Everbright Securities Co. Ltd. |
| Tianyi Yan | Goldman Sachs |
| Changyan Xie | Guosen Securities Co., Ltd. |